Sandra Milligan, MD, JD, currently serves as Vice President Global Regulatory Therapeutic Area Head for Inflammation, Virology and Ophthalmology for Genentech Inc., a Member of the Roche Group, where she develops and directs global strategic regulatory plans to facilitate and optimize product development, regulatory approval, and commercialization. She previously served at Amgen for almost 10 years in various roles, including Global Regulatory Therapeutic Area Head for the Bone franchise, as Head of Regulatory Communications Strategy & Operations, and as Senior Counsel, for the Development, Regulatory & Compliance Law Group, where she provided strategy for development, regulatory and safety groups. In addition to serving on the DIA Board of Directors, Sandra has served as a DIA Annual Meeting session chair and as co-chair of the Public Policy/Health Care Compliance/Regulatory Law Annual Meeting track. She is the 2013 Annual Meeting Program Chair. Sandra is a graduate of The George Washington University School of Medicine and Health Sciences, and of the Georgetown University Law Center.